Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ezose Sciences and Hirosaki University have signed a glycomics research collaboration to discover new biomarkers for use in monitoring the progression of prostate cancer and other urological cancers.
Subscribe to our email newsletter
Under the research collaboration, serum and urine samples collected by Hirosaki investigators from well-characterized patient and control populations in Japan, will be examined.
The glycan analysis will be conducted by Ezose leveraging its GlycanMap technology platform at its US laboratories.
Ezose R&D vice president Hidehisa Asada said, "Given the already established clinical utility of glycan-based biomarkers in certain cancers, we believe that further studies in oncology hold promise for identifying other novel biomarkers that could help guide clinical practice."
As a part of the agreement, Ezose received exclusive rights from Hirosaki to develop and commercialize new biomarkers resulting from the collaboration.